$IOBT ReversalMorgan Stanley Initiates Coverage On IO Biotech with Overweight Rating, Announces Price Target of $21
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops disruptive immune modulating anti-cancer therapies in Denmark. The company's lead product candidate, IO102-IO103, is designed